Form 8-K

8-K — HeartSciences Inc.

Accession: 0001213900-26-091893

Filed: 2026-08-20

Period: 2026-08-20

CIK: 0001468492

SIC: 6199 (FINANCE SERVICES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0302835-8k_heart.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED AUGUST 20, 2026. (ea030283501ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0302835-8k_heart.htm · Sequence: 1

false

0001468492

2026-08-20

0001468492

us-gaap:CommonStockMember

2026-08-20

0001468492

HSCS:WarrantsMember

2026-08-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 20, 2026

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its

Charter)

Texas

001-41422

26-1344466

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

550 Reserve Street, Suite 360

Southlake, Texas

76092

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including

Area Code: (682) 237-7781

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

HSCS

The Nasdaq Stock Market LLC

Warrants

HSCSW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 20, 2026, Fortitude

Mining Holdings, Inc., a Delaware corporation (“Fortitude”), issued a press release announcing its financial and operating

highlights for the quarter ended June 30, 2026, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this

“Current Report”).

As previously reported, on

June 23, 2026, HeartSciences Inc., a Texas corporation (“HeartSciences”), Fortitude, Fortitude Mining HoldCo, LLC

and Cordis Acquisition, LLC, entered into an Agreement and Plan of Merger (the “Merger Agreement”) relating to their

proposed business combination (the "Proposed Transaction”).

The information provided

in this Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”

for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the

liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of HeartSciences under the

Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation

language in such filing, except as otherwise expressly set forth by specific reference in such filing.

Additional Information and Where to Find It

Communications related

to each of Fortitude and HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material

in respect of the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences filed a preliminary proxy

statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) on July 27, 2026 and may file

additional relevant materials with the SEC. Following the filing of a definitive proxy statement with the SEC, HeartSciences will

mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the special meeting relating to the

Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR

SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR

MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED

TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION

AND RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH

MATTERS. The preliminary proxy statement, the definitive proxy statement and other relevant materials in connection with the

Proposed Transaction (when they become available), and any other documents filed by HeartSciences with the SEC, may be obtained free

of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents

filed with the SEC or by sending a request to the HeartSciences Investor Relations Department at

investorrelations@heartsciences.com.

NEITHER THE SEC NOR ANY STATE

SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE

PROPOSED TRANSACTION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS CURRENT REPORT. ANY

REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Cautionary Note Regarding Forward-Looking Information

Communications may contain

forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements

generally can be identified by the use of words such as “aim,” “anticipate,” “expect,” “plan,”

“could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,”

“project,” “potential,” “target,” “objective,” “intend,” and other words of

similar meaning, but the absence of these words does not mean that a statement is not forward-looking. All statements HeartSciences and/or

Fortitude make in communications that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements

are based on management’s current expectations and assumptions as of the date of such communication and are subject to a number

of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed

or implied by such statements, which may include, without limitation, the following: the risk that the Proposed Transaction may not be

completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including

obtaining the requisite approval of the HeartSciences’ shareholders; market, macroeconomic, or other conditions that could adversely

affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management

of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile nature of the price

of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty regarding

digital assets generally. Additional factors that may cause actual results to differ materially from those expressed or implied by the

forward-looking statements in such communications are discussed in HeartSciences’ filings with the SEC, including its Annual Report

on Form 10-K, filed with the SEC on July 23, 2026 and its other reports filed with the SEC from time to time, and are discussed in the

preliminary proxy statement filed by HeartSciences with the SEC in connection with the Proposed Transaction. Readers are cautioned not

to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to

update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required

by applicable law. Any forward-looking statements made in such communications are made as of the date of the communication.

Participants in the Solicitation

HeartSciences and Fortitude,

their respective directors and executive officers, and certain executive officers of Digital Currency Group, Inc., the parent company

of Fortitude, may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders with respect to the

Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect interests in the

Proposed Transaction, by security holdings or otherwise, is set forth in the preliminary proxy statement and other materials filed or

that may be filed with the SEC in connection with the Proposed Transaction.

No Offer or Solicitation

Any information contained

herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation

to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval

in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities

in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and

conditions of the Merger Agreement, which contain the full terms and conditions of the Proposed Transaction.

Item 9.01 Financial Statements and Exhibits

(a) Exhibits

Number

Description

99.1*

Press Release, dated August 20, 2026.

104*

Cover Page Interactive Data File (embedded within the Inline XBRL document).

Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEARTSCIENCES INC.

Date: August 20, 2026

By:

/s/ Andrew Simpson

Name:

Andrew Simpson

Title:

President, Chief Executive Officer and

Chairman of the Board of Directors

EX-99.1 — PRESS RELEASE, DATED AUGUST 20, 2026.

EX-99.1

Filename: ea030283501ex99-1.htm · Sequence: 2

Exhibit 99.1

Fortitude Provides Second Quarter 2026 Financial

and Operating Highlights

Fortitude reported strong financial performance

with revenue of $20.9 million and Adjusted EBITDA of $8.5 million

Continued momentum in core mining operations

with approximately 33,646 ZEC mined during the quarter at an average realized hash rate of 4.0 GSol/s, with recent site and fleet

expansions bringing the owned-and-operated power portfolio to 60+ MW

Fortitude purchased approximately $1,000,000

of HeartSciences common stock in a private placement, with the proposed business combination expected to close in H2 2026

FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude

Mining Holdings, Inc. (“Fortitude”), a vertically-integrated digital asset mining platform anchored in Zcash, today provided

financial and operating highlights for the three-month period ended June 30, 2026.

“This was a strong quarter for Fortitude and a clear demonstration

of the momentum building in our vertically-integrated strategy,” said Andrea Childs, CEO of Fortitude. “We mined approximately

33,646 ZEC at an average operating hash rate of 4.0 GSol/s. As we work to advance toward the public markets via our proposed business

combination with HeartSciences, we remain thrilled about the opportunity ahead and our ability to execute on it.”

“Fortitude delivered a strong cash-flowing quarter in Q2, generating

$20.9 million in revenue driven by continued ZEC hashprice and hashrate performance across our fleet,” added Erik Ellingson, CFO

of Fortitude. “This translated into robust operating cash flow indicated by adjusted EBITDA of $8.5 million, reinforcing the strength

of our ZEC-focused mining strategy as we continue to prepare to close our proposed business combination with HeartSciences.”

Q2 Financial and Operating Highlights

Key financial and operational

highlights for the quarter include:

● Quarterly

revenue of $20.9 million

● Adjusted

EBITDA1 of $8.5 million

● ZEC

average operating hash rate 4.0 GSol/s

● ZEC

mined of approximately 33,646

● Total

controlled power capacity of 60+ MW across seven sites

Proposed Business Transaction

As previously announced on June 23, 2026, Fortitude and HeartSciences

Inc. (Nasdaq: HSCS) (“HeartSciences”) an AI-powered medical technology company, entered into a definitive agreement providing

for a proposed business combination (the “Proposed Transaction”). The Proposed Transaction is intended to bring a leading vertically-integrated

Zcash mining platform to the public markets, and is expected to close in H2 2026.

Fortitude Investment in HeartSciences

On August 12, 2026, Fortitude and HeartSciences

entered into a subscription agreement pursuant to which Fortitude purchased an aggregate of 411,522 shares of HeartSciences’ common stock

in a private placement (the “Subscription”), at a negotiated VWAP of $2.43 per share1, a 22% premium to the closing

price of HeartSciences’ common stock on August 12, 2026. The Subscription supports HeartSciences’ operating expenses in the period leading

up to the expected closing of the Proposed Transaction and reflects Fortitude’s commitment to a successful close.

1 Represents the 30

trading day Volume Weighted Average Price for HeartSciences common stock through August 11,

2026.

Following the Subscription, Fortitude owns approximately 9.4%2

of HeartSciences’ issued and outstanding common stock. The shares issued to Fortitude in the Subscription are ordinary shares of HeartSciences’

common stock, without any additional rights or preferences. Additionally, the exchange ratio under the merger agreement relating to the

Proposed Transaction is unchanged, and Fortitude will not receive any additional shares at the closing of the Proposed Transaction as

a result of the Subscription. The investment is intended to strengthen the balance sheet of HeartSciences and reflects Fortitude’s continued

conviction in the Proposed Transaction and its ability to close.

About Fortitude

Fortitude, currently wholly-owned by DCG,

is an institutional-scale, vertically integrated venture mining platform operating across the Proof-of-Work ecosystem and anchored in

Zcash. Fortitude pairs self-mining operations with an owned data center footprint, a diversified power portfolio backed by competitive

long-term contracts, and disciplined capital allocation to identify and scale high-conviction opportunities in emerging Proof-of-Work

ecosystems, beginning with its leadership position in the Zcash network. Fortitude is led by an experienced team of operators, capital

markets professionals, and digital asset specialists with a track record of identifying and scaling high-conviction opportunities and

building privacy-preserving digital asset infrastructure.

For

more information, visit www.fortitudemining.com

and follow Fortitude on X at @FortitudeCrypto

About HeartSciences

HeartSciences is a healthcare information

technology company advancing the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™

Platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device

is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.

For more information,

please visit: www.heartsciences.com

and follow HeartSciences on X @HeartSciences.

Cautionary Note Regarding Forward-Looking

Information

This press release contains forward-looking

statements. These forward-looking statements generally can be identified by the use of words such as “aim,” “anticipate,”

“expect,” “design,” “plan,” “will,” “would,” “believe,” “estimate,”

“goal,” “intend,” and other words of similar meaning, but the absence of these words does not mean that a statement

is not forward-looking. These forward-looking statements include, but are not limited to, express or implied statements relating to Fortitude

and its expectations concerning the timing of the Proposed Transaction and the expectation that the Proposed Transaction will bring Fortitude

to the public markets and its expectations around HeartSciences’ use of proceeds from the Subscription. All statements contained

in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

2 The percentages reported

herein are based upon HeartSciences’ outstanding shares of Common Stock as reported

in the HeartSciences Current Report on Form 8-K, filed with the U.S. Securities and Exchange

Commission (“SEC”) on August 18, 2026.

-2-

These

forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and

are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to diﬀer materially

from those expressed or implied by such statements, including, without limitation, the following: the risk that the Proposed Transaction

may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction,

including obtaining the requisite approval of the HeartSciences shareholders; market, macroeconomic, or other conditions that could adversely

aﬀect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the

management of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile nature

of the price of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty

regarding digital assets generally. Additional factors that may cause actual results to diﬀer materially from those expressed or

implied by the forward-looking statements in this press release are discussed in the preliminary proxy statement on Schedule 14A, filed

by HeartSciences with the SEC on July 27, 2026, in connection with the Proposed Transaction, HeartSciences’ 2026 Annual Report

on Form 10-K, filed with the SEC on July 23, 2026, and other reports filed with the SEC from time to time.

Readers are cautioned not to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims

any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise,

except as required by applicable law. All forward-looking statements are made as of the date of this press release.

Non-GAAP Financial Measures

EBITDA & Adjusted EBITDA

Fortitude has presented certain

financial measures in this press release that are not recognized under U.S. Generally Accepted Accounting Principles (“GAAP”). Specifically,

Fortitude has presented “EBITDA” and “Adjusted EBITDA” (each as further described below). References to “EBITDA”

mean earnings before interest, taxes, depreciation and amortization and “Adjusted EBITDA” means EBITDA, adjusted for

non-recurring transaction related expenses, including advisory, legal, accounting, and regulatory fees, non-recurring litigation related

expenses, realized gain/losses on disposal of equipment. Fortitude uses non-GAAP measures in its operational and financial decision making

and believes that such non-GAAP numbers are more representative of the performance of the business and thus instructive for its strategic

planning. Specifically, with respect to Adjusted EBITDA, Fortitude believes it is useful to exclude certain items in order to allow for

period-over-period comparisons on a more consistent basis and to focus on what Fortitude regards to be a more meaningful indicator for

evaluating the underlying operating performance of the business. Fortitude believes that these non-GAAP financial measures, while not

a substitute for GAAP financial measures, provide investors with (i) an improved ability to evaluate its underlying performance and

(ii) greater transparency of the key performance metrics used by Fortitude’s management with respect to operational and financial

decision making. In evaluating Adjusted EBITDA, you should be aware that in the future Fortitude may incur expenses that are the same

as or similar to some of the adjustments in such presentation. The non-GAAP financial measures presented herein are provided as supplemental

information to Fortitude’s performance measures calculated in accordance with GAAP and should not be considered in isolation or

as a substitute for GAAP. Non-GAAP measures have limitations as an analytical tool. Some of these limitations are: (i) Adjusted

EBITDA excludes certain transaction-related expenses, non-recurring legal expenses we have incurred, such as litigation costs and one-time

accounting charges, gain/losses on disposal of equipment (ii) although depreciation and amortization are non-cash charges, the assets

being depreciated and amortized may have to be replaced in the future, and the cash requirements for such replacements are not reflected

in Adjusted EBITDA; (iii) the omission of the amortization expense associated with Fortitude’s intangible assets further limits

the usefulness of Adjusted EBITDA; and (iv) Adjusted EBITDA does not include the payment of taxes, which is a necessary element of

Fortitude’s operations. Because of these limitations, such non-GAAP measures should not be considered as an alternative to profit

or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Fortitude’s

management compensates for these limitations by not viewing the non-GAAP measures in isolation and specifically by using other GAAP measures

to measure Fortitude’s operating performance. Further, non-GAAP financial measures do not have any standardized meaning prescribed

under GAAP and therefore may not be comparable to other issuers. As a result, you should not consider such performance measures in isolation

from, or as a substitute analysis for, Fortitude’s results of operations as determined in accordance with GAAP.

-3-

GAAP Net Income (Loss) to Adj. EBITDA Reconciliation

Adjusted. EBITDA Reconciliation

$ in millions

Q2 2026

Net Income (Loss)

$ (9.5 )

plus: Impairment of mining equipment

10.3

plus: Depreciation and amortization

5.6

plus: Interest expenses

0.1

plus: Income tax benefit

(1.5 )

EBITDA

$ 4.9

plus: Non-recurring transaction related expenses(1)

3.6

plus: Non-recurring litigation related expenses

0.3

plus: Realized gain/loss on disposal of equipment

(0.3 )

Adjusted EBITDA

$ 8.5

(1) Non-recurring transaction related expenses including advisory,

legal, accounting, and regulatory fees.

Additional Information About the Proposed

Transaction and Where to Find It

This

press release may be deemed solicitation material in respect of the Proposed Transaction. In connection with the Proposed Transaction,

HeartSciences has filed a preliminary proxy statement on Schedule 14A and may file additional relevant materials with the SEC. Following

the filing of a definitive proxy statement with the SEC, HeartSciences will mail the definitive proxy statement and a proxy card to each

shareholder entitled to vote at the special meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES

ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH

THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT

INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. THIS PRESS RELEASE DOES NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE

CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS AND IS NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION

OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The preliminary proxy statement, the definitive proxy statement and other relevant

materials in connection with the Proposed Transaction (when they become available), and any other documents filed by HeartSciences with

the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov.

In addition, investors and shareholders may obtain free copies of the documents filed with the SEC or by sending a request to the HeartSciences

Investor Relations Department at investorrelations@heartsciences.com.

-4-

Participants in the Solicitation

HeartSciences and Fortitude, their respective

directors and executive officers, and certain executive officers of Digital Currency Group, Inc. may be deemed to be participants in the

solicitation of proxies from HeartSciences’ shareholders with respect to the Proposed Transaction. Information regarding the identity

of the potential participants, and their direct or indirect interests in the Proposed Transaction, by security holdings or otherwise,

is set forth in the preliminary proxy statement and other materials that have been or may be filed with the SEC in connection with the

Proposed Transaction.

No Offer or Solicitation

This press release and the information contained

herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation

to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval

in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities

in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and

conditions of the merger agreement, which contain the full terms and conditions of the Proposed Transaction.

Investor

Relations and Media Contact:

ICR

Phone:

917-375-9457

Email: IR@fortitudemining.com

-5-

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 20, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 20, 2026

Entity File Number

001-41422

Entity Registrant Name

HEARTSCIENCES INC.

Entity Central Index Key

0001468492

Entity Tax Identification Number

26-1344466

Entity Incorporation, State or Country Code

Entity Address, Address Line One

550 Reserve Street

Entity Address, Address Line Two

Suite 360

Entity Address, City or Town

Southlake

Entity Address, State or Province

Entity Address, Postal Zip Code

76092

City Area Code

682

Local Phone Number

237-7781

Written Communications

false

Soliciting Material

true

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

HSCS

Security Exchange Name

NASDAQ

Warrants

Title of 12(b) Security

Warrants

Trading Symbol

HSCSW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HSCS_WarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: